Conotoxin peptide κ-CPTX-BTL02, preparation method therefor, and uses thereof

Patent metadata

Field	Value
Publication number	US-10246490-B2
Application number	US-201415539720-A
Country	US
Kind code	B2
Filing date	Dec 26, 2014
Priority date	Dec 26, 2014
Publication date	Apr 2, 2019
Grant date	Apr 2, 2019

Abstract

Provided is a new conotoxin peptide κ-CPTx-btl02. The conotoxin peptide κ-CPTx-btl02 has derivative polypeptide that has an amino acid sequence indicated by SEQ ID NO:1, or has derivative polypeptide that has an amino acid sequence indicated by SEQ ID NO:1 and that is formed after substitution, addition or deletion of one or more amino acids are performed and has original functions. Also provided is polynucleotide for coding the peptide, comprising a constructed body of the polynucleotide, an expression carrier and transformed cells. A peptide preparation method and uses in the treatment of diseases related to a calcium ion channel.

First claim

The invention claimed is:

1. A method of inhibiting a calcium ion channel, the method comprising contacting the calcium ion channel with a conotoxin peptide κ-CPTx-btl02, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 1, and wherein the peptide contains three pairs of disulfide bonds.

2. The method according to claim 1 , wherein the calcium ion channel is a high-voltage activated calcium ion channel.

3. A method of inhibiting a calcium ion channel in a subject in need thereof, the method comprising administering to the subject a conotoxin peptide κ-CPTx-btl02, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 1, and wherein the peptide contains three pairs of disulfide bonds.

4. The method according to claim 3 , wherein the calcium ion channel is a high-voltage activated calcium ion channel.

Assignees

• Bgi Shenzhen

Inventors

• Liu Jie
• Lin Zhilong
• Wen Bo
• Tong Ting
• Mo Fen
• Peng Chao
• Shi Qiong

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K1/061

  using protecting groups · CPC title

• A61K38/10

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• C12N5/10

  Cells modified by introduction of foreign genetic material · CPC title

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title